SecBot SecBot
SECBOTREPLAY Home › Report › PYXS

PYXS · Pyxis Oncology announced preclinical data showing that a mouse analog…

Pyxis Oncology · PRESS-RELEASE filed Apr 17, 2026 at 16:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 17, 2026 at 16:05 ET

Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-dependent tumor growth inhibition and synergistic anti-tumor activity when combined with anti-PD-1 therapy in an immunotherapy-refractory head and neck cancer model. These findings support ongoing clinical trials of MICVO as monotherapy and in combination with pembrolizumab for recurrent/metastatic HNSCC.

  • Preclinical data show maMICVO monotherapy inhibited tumor outgrowth in a syngeneic HNSCC model in a dose-dependent manner, with 6 mg/kg showing strongest effect
  • Combination of maMICVO and anti-mouse PD-1 showed synergistic anti-tumor activity in an immunotherapy-refractory model, with greater tumor control than either agent alone
  • maMICVO modulated the tumor immune environment by reducing regulatory T cells (Tregs), increasing CD8+ T cell-to-Treg ratio, and enhancing progenitor exhausted T cells responsive to anti-PD-1
  • Data to be presented at AACR 2026; supports ongoing Phase 1/2 trials of MICVO alone and with pembrolizumab in R/M HNSCC

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access